- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Skin discoloration.
Displaying page 1 of 1.
EudraCT Number: 2004-003215-22 | Sponsor Protocol Number: vit-001 | Start Date*: 2005-02-04 | |||||||||||
Sponsor Name:Antonio Noda Cabrera | |||||||||||||
Full Title: Ensayo clínico piloto, unicéntrico, aleatorizado, doble ciego, con dos grupos paralelos sobre el efecto del Tacalcitol en pacientes afectos de vitíligo. | |||||||||||||
Medical condition: vitiligo vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002960-29 | Sponsor Protocol Number: 79048 | Start Date*: 2020-02-18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Merete Haedersdal [Bispebjerg Hospital] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Assessing the efficacy of image-guided laser-assisted Enstilar® delivery for treatment of psoriatic nails - a proof-of-concept, single-center, prospective, open-label, randomized, clinical trial wi... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Nail psoriasis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000304-26 | Sponsor Protocol Number: GS-US-162-0112 | Start Date*: 2015-01-29 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa with Continued Access to Emtricitabine. | |||||||||||||
Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004110-10 | Sponsor Protocol Number: 2ABC | Start Date*: 2017-12-21 | ||||||||||||||||
Sponsor Name:Medical University of Warsaw | ||||||||||||||||||
Full Title: Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The t... | ||||||||||||||||||
Medical condition: Scar or cutis laxa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-005085-21 | Sponsor Protocol Number: KCSA-03 | Start Date*: 2005-12-13 |
Sponsor Name:Dermal Laboratories Limited | ||
Full Title: Scalp lotion for the treatment of pityriasis capitis (severe dandruff) and seborrhoeic dermatitis. | ||
Medical condition: Seborrhoeic dermatitis and pityriasis capitis of the scalp. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005413-40 | Sponsor Protocol Number: CAIN457A2313 | Start Date*: 2013-04-25 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm effi... | |||||||||||||
Medical condition: Moderate to severe nail psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001936-11 | Sponsor Protocol Number: 3074K4-3339-WW | Start Date*: 2009-03-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Inc... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated skin and skin structure infection (cSSSI) with or without methicillin-resistant Staphylococcus aureus (MRSA) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: HU (Completed) BE (Completed) GB (Completed) Outside EU/EEA | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012304-55 | Sponsor Protocol Number: 192024-038 | Start Date*: 2009-07-15 | |||||||||||
Sponsor Name:Allergan Ltd | |||||||||||||
Full Title: A One Year, Multicenter, Double-Masked, Randomized, Parallel-Group Study Assessing the Safety and Efficacy of Once Daily Application of Bimatoprost 0.03% Solution Compared to Vehicle to Treat Hypot... | |||||||||||||
Medical condition: Hypotrichosis of the eyelashes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001723-12 | Sponsor Protocol Number: ARIVA_venous | Start Date*: 2020-05-28 |
Sponsor Name:Universitätsspital Zürich, Klinik für Angiologie | ||
Full Title: Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome | ||
Medical condition: Post-thrombotic syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001125-15 | Sponsor Protocol Number: ATB-202 | Start Date*: 2018-07-16 | |||||||||||||||||||||
Sponsor Name:Atox Bio | |||||||||||||||||||||||
Full Title: Phase III, randomized, double-blind, placebo controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI) | |||||||||||||||||||||||
Medical condition: Necrosis of soft tissue infections (NSTI) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000956-42 | Sponsor Protocol Number: VRX-RET-E22-304 | Start Date*: 2006-09-20 |
Sponsor Name:Valeant Pharmaceuticals, North America | ||
Full Title: A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302) | ||
Medical condition: Adult epilepsy patients with partial-onset seizures | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) HU (Completed) BE (Completed) ES (Completed) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
